|
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3078-3085.
Prepublished online as a Blood First Edition Paper on July 29, 2004; DOI 10.1182/blood-2004-03-1036.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
Wolfgang Kern,
Daniela Voskova,
Claudia Schoch,
Wolfgang Hiddemann,
Susanne Schnittger, and
Torsten Haferlach
From the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Muenchen, Germany.
Quantification of minimal residual disease (MRD) reveals significant prognostic information in patients treated for acute myeloid leukemia (AML). The application of multiparameter flow cytometry (MFC) for MRD assessment has resulted in significant prognostic information in selected cases in previous analyses. We analyzed MRD in unselected patients with AML in complete remission (CR) after induction (n = 58) and consolidation (n = 62) therapies. By using a comprehensive panel of monoclonal antibodies we identified at least one leukemia-associated aberrant immunophenotype (LAIP) in each patient. The degree of reduction between diagnosis and CR in LAIP-positive cells (log difference [LD]) as a continuous variable was significantly related to relapse-free survival (RFS) both after induction (P = .0001) and consolidation (P = .000 08) therapies, respectively. The LD determined after consolidation therapy was the only parameter related to overall survival (OS) (P = .005). Separation of patients based on the 75th percentile of LD after consolidation therapy resulted in groups with highly different RFS (83.3% versus 25.7%, P = .0034) and OS (87.5% versus 51.4%, P = .0507) at 2 years. Multivariate analysis identified LD as an independent prognostic factor for RFS at both checkpoints. MFC-based quantification of MRD reveals important prognostic information in unselected patients with AML in addition to cytogenetics and should be further evaluated and used in clinical trials.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. C. Bene and J. S. Kaeda
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet
Haematologica,
August 1, 2009;
94(8):
1135 - 1150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Al-Mawali, D. Gillis, and I. Lewis
The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia
Am J Clin Pathol,
January 1, 2009;
131(1):
16 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Hess, N. Feller, F. Denkers, A. Kelder, P. A. Merle, M. C. Heinrich, A. Harlow, J. Berkhof, G. J. Ossenkoppele, Q. Waisfisz, et al.
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia
Haematologica,
January 1, 2009;
94(1):
46 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Maurillo, F. Buccisano, M. I. Del Principe, G. Del Poeta, A. Spagnoli, P. Panetta, E. Ammatuna, B. Neri, L. Ottaviani, C. Sarlo, et al.
Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia
J. Clin. Oncol.,
October 20, 2008;
26(30):
4944 - 4951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cilloni, F. Messa, F. Arruga, I. Defilippi, E. Gottardi, M. Fava, S. Carturan, R. Catalano, E. Bracco, E. Messa, et al.
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
Haematologica,
June 1, 2008;
93(6):
921 - 924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients
Blood,
March 1, 2008;
111(5):
2527 - 2537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Blood,
October 1, 2007;
110(7):
2659 - 2666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Langebrake, U. Creutzig, M. Dworzak, O. Hrusak, E. Mejstrikova, F. Griesinger, M. Zimmermann, and D. Reinhardt
Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group
J. Clin. Oncol.,
August 1, 2006;
24(22):
3686 - 3692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Steinbach, A. Schramm, A. Eggert, M. Onda, K. Dawczynski, A. Rump, I. Pastan, S. Wittig, N. Pfaffendorf, A. Voigt, et al.
Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia
Clin. Cancer Res.,
April 15, 2006;
12(8):
2434 - 2441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, and G. J. Schuurhuis
High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival
Clin. Cancer Res.,
September 15, 2005;
11(18):
6520 - 6527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Haferlach, A. Kohlmann, S. Schnittger, M. Dugas, W. Hiddemann, W. Kern, and C. Schoch
Global approach to the diagnosis of leukemia using gene expression profiling
Blood,
August 15, 2005;
106(4):
1189 - 1198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
